Prone posi

Prone positioning offers limited benefit in preventing ventilation escalation among infants with bronchiolitis

Placing infants with moderate-to-severe acute viral bronchiolitis in the prone position while receiving high-flow nasal cannula (HFNC) support did not significantly lower the likelihood of escalation to noninvasive or invasive ventilation, according to results of the PROPOSITIS multicentre randomised clinical trial published in JAMA. The findings, drawn from 15 French paediatric intermediate and ICUs, leave open the question of whether prone positioning offers a meaningful benefit in this population, with the authors noting that a wide confidence interval (CI) around the observed effect est...

Maternal RSV vaccination reduces infant hospitalisations by nearly 70%

Maternal vaccination with the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine was associated with a 67.6% reduction in RSV-related acute respiratory illness hospitalisations and a 69.0% reduction in RSV-related lower respiratory tr...

Omalizumab shows favourable safety profile in very young children with food allergies

An interim analysis of the OUtMATCH trial found that omalizumab had a safety profile comparable to placebo in children aged 1 to 5 years with multiple food allergies, with most adverse events being mild and no treatment-related anaphylaxis reported. ...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
The RA Par
5:38

The RA Paradigm Shift: New Insights into Pathogenesis and a Pipeline of Promise

Presenter: Elena Nikiphorou
Rheumatology
EULAR 2026
Assessment
4:60

Assessment of Disease Activity in Psoriatic Arthritis

Presenter: Michael Zauner
Rheumatology
EULAR 2026
Tired Is N
9:42

Tired Is Not Just a State of Mind: Addressing Pathological Fatigue at EULAR 2026

Presenter: Elena Elefante
Rheumatology
EULAR 2026
Advanced M
9:34

Advanced Management in Rheumatoid Arthritis: Critical Updates from EULAR 2026

Presenter: Ruxandra Ionescu
Rheumatology
EULAR 2026
Transition
9:50

Transitioning Young Patients with Autoinflammatory Diseases to Adult Care: Implications for Daily Clinical Management

Presenter: Marco Gattorno
Rheumatology
EULAR 2026
Under the
2:39

Under the Surface: New Perspectives in Lupus with TLR7/8 Inhibition

Presenter: Victoria Werth
Rheumatology
EULAR 2026
Clinical M
13:38

Clinical Manifestations and Disease Course in Systemic Sclerosis

Presenter: Cristiana Sieiro Santos
Rheumatology
EULAR 2026
Chest HRCT
4:49

Chest HRCT in Detecting, Staging and Follow Up of SARD-ILD

Presenter: Muriel Elhai
Rheumatology
EULAR 2026
Highlights
4:42

Highlights of EULAR 2026

Presenter: Xenofon Baraliakos
Rheumatology
EULAR 2026
Novel Trea
2:50

Novel Treatment Horizons in Lupus: Key Updates from EULAR 2026

Presenter: Victoria Werth
Rheumatology
EULAR 2026
From Diagn
9:18

From Diagnosis to Family Building: Navigating Fertility in RMDs

Presenter: Laura Andreoli
Rheumatology
EULAR 2026
Impact of
4:16

Impact of Sonelokimab on Clinical and Imaging Outcomes in Axial Spondyloarthritis: Results of a Phase 2 Study

Presenter: Xenofon Baraliakos
Rheumatology
EULAR 2026
Novel Deve
4:60

Novel Development in Treatment of Lupus

Presenter: Anca Dinu Askanase
Rheumatology
EULAR 2026
Managing C
6:01

Managing Comorbidities in Rheumatoid Arthritis for Better Outcome

Presenter: Claudia Iannone
Rheumatology
EULAR 2026
Managing C
7:60

Managing Comorbidities in Systemic Sclerosis to Achieve Better Outcome

Presenter: Claudia Iannone
Rheumatology
EULAR 2026
Pain Manag
5:23

Pain Management in Rheumatological Diseases

Presenter: Jasminka Milas-Ahic
Rheumatology
EULAR 2026
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology